<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091234</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06031</org_study_id>
    <secondary_id>EORTC-06031</secondary_id>
    <nct_id>NCT00091234</nct_id>
  </id_info>
  <brief_title>Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
  <acronym>AML-19</acronym>
  <official_title>Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and
      either kill them or deliver cancer-killing substances to them without harming normal cells.
      It is not yet known whether gemtuzumab ozogamicin is more effective than standard supportive
      care in treating older patients who have acute myeloid leukemia.

      PURPOSE: This randomized phase II/III trial is studying two different gemtuzumab ozogamicin
      regimens to see how well they work compared to standard supportive care in treating older
      patients with previously untreated acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the feasibility, toxicity, and antileukemic activity of two different dosing
           regimens of gemtuzumab ozogamicin (GO) vs standard supportive care in older patients
           with previously untreated acute myeloid leukemia who are not candidates for intensive
           chemotherapy. (phase II)

        -  Compare the efficacy and toxicity of the best dosing regimen of GO selected from phase
           II vs standard supportive care, in terms of overall survival, in these patients. (phase
           III)

      OUTLINE: This is a randomized, open-label, multicenter phase II study followed by a phase III
      study. Patients are stratified according to age (61 to 75 vs 76 to 80 vs 81 and over),
      CD33-positivity of bone marrow blasts (&lt; 20% vs 20-80% vs &gt; 80% vs unknown), initial WBC
      before hydroxyurea administration (&lt; 30,000/mm^3 vs ≥ 30,000/mm^3), WHO performance status
      (0-1 vs 2 vs 3-4), and participating center.

        -  Phase II: Patients are randomized to 1 of 3 treatment arms.

             -  Arm I: Patients receive gemtuzumab ozogamicin (GO) IV over 2 hours on days 1 and 8.
                Patients with stable or responding disease at day 36 receive GO IV over 2 hours
                every 4 weeks for up to 8 courses in the absence of disease progression or
                unacceptable toxicity.

             -  Arm II: Patients receive GO IV over 2 hours on days 1, 3, and 5. Patients with
                stable or responding disease at day 36 receive GO IV over 2 hours every 4 weeks for
                up to 8 courses in the absence of disease progression or unacceptable toxicity.

             -  Arm III: Patients receive standard supportive care.

        -  Phase III: Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive the selected treatment (arm I or arm II) from phase II.

             -  Arm II: Patients receive standard supportive care. Patients who receive GO
                treatment are followed monthly for 1 year and then every 3 months thereafter.
                Patients who receive standard supportive care are followed at least every 4 weeks.

      PROJECTED ACCRUAL: A total of 259 patients (75 for phase II [25 per treatment arm] and 184
      for phase III [92 per treatment arm]) will be accrued for this study within 2.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients able to start continuation therapy (Phase II)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Phase III)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remission (CR+CRp)by the end of continuation therapy, for patients in the GO arms (Phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Phase II)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (CTCAE grading), including time to hematological recovery (Phase II &amp; III)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remisison (CR+CRp) by the end of induction and by the end of continuation therapy, for patients in GO arm (Phase III)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival for patients who reached CR or CRp (Phase III)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival from randomization for patients in GO arm (Phase III)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">279</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed acute myeloid leukemia (AML)

               -  At least 20% bone marrow blasts by bone marrow aspiration or biopsy

               -  All subtypes except M3 (acute promyelocytic leukemia) are allowed

          -  Previously untreated primary or secondary disease (including AML after myelodysplastic
             syndromes)

          -  Ineligible for intensive chemotherapy, as defined by 1 of the following criteria:

               -  61 to 75 years old AND WHO performance status &gt; 2 AND/OR unwilling to receive
                  intensive chemotherapy

               -  Over 75 years old

          -  No blast crisis of chronic myeloid leukemia

          -  No AML supervention after other myeloproliferative disease

          -  WBC &lt; 30,000/mm^3 and meets 1 of the following criteria:

               -  WBC &lt; 30,000/mm^3 at diagnosis AND had no prior treatment with hydroxyurea

               -  WBC ≥ 30,000/mm^3 at diagnosis AND received mandatory pretreatment with
                  hydroxyurea (up to 14 days duration) until WBC &lt; 30,000/mm^3

          -  No active CNS leukemia

        PATIENT CHARACTERISTICS:

        Age

          -  See Disease Characteristics

          -  61 and over

        Performance status

          -  See Disease Characteristics

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Cardiovascular

          -  No arrhythmia requiring chronic treatment

          -  No congestive heart failure

          -  No symptomatic ischemic heart disease

          -  No other severe cardiovascular disease

        Pulmonary

          -  No severe pulmonary dysfunction ≥ grade 3

        Other

          -  No alcohol abuse

          -  No severe neurological or psychiatric disease

          -  No active uncontrolled infection or severe systemic infection

          -  No other malignancy

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance and follow-up

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)

          -  No concurrent antiangiogenic drugs

        Chemotherapy

          -  See Disease Characteristics

          -  Concurrent low-dose cytostatic agents (i.e., thioguanine or mercaptopurine) allowed
             for palliative care (standard supportive care arm only)

        Endocrine therapy

          -  Prior corticosteroids (duration ≤ 14 days ) for primary or secondary AML allowed

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No other concurrent cytotoxic drugs

          -  No other concurrent experimental therapy

          -  No concurrent tyrosine kinase inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Amadori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EORTC - AZIENDA OSPEDALLERA UNIVERSITARIA - POLICLINICO TOR VERGATA, IT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuliana Alimena</last_name>
    <role>Principal Investigator</role>
    <affiliation>GIMEMA - Universita Degli Studi &quot;La Sapeinza&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hilde Breyssens</last_name>
    <email>hilde.breyssens@eortc.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>32-3-280-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>32-50-45-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>32-2-541-3510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>32-2-555-3806</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>32-03-821-3375</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>32-4-366-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>328-721-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S Donato, USL-8</name>
      <address>
        <city>Arezzo cap</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-080-547-8660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita Di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Binaghi</name>
      <address>
        <city>Cagliari</city>
        <zip>090100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-070-609-3149</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico A. Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-070-609-5204</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale A Pugliese</name>
      <address>
        <city>Cantanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-095-743-5915</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale A. Pugliese</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-961-883-346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-532-209-100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-083-266-1235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-059-422-4373</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Montefiascone</name>
      <address>
        <city>Montefiascone</city>
        <zip>I-01027</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-07-618-331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli</name>
      <address>
        <city>Naples</city>
        <zip>80127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-081-747-3011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-091-655-2321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale La Maddalena - Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-91-680-6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-0521-702-441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Monteluce</name>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo F. Martelli, MD</last_name>
      <phone>39-75-5783219</phone>
      <email>ematol@unipg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <zip>I-61100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Lucarelli</last_name>
      <phone>0039-0721-36424</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Pescara</name>
      <address>
        <city>Pescara</city>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Sta. Maria Delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-544-285-247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-06-20-901</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant' Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-06-5100-2569</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Libero Istituto Universitario Campus Bio-Medico</name>
      <address>
        <city>Rome</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact</last_name>
      <phone>39-06-2254-1366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto Primo</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Mandelli</last_name>
      <phone>39-06-85-79-51</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-06-4985-2201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-06-3015-5556</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. San Giovanni-Addolorata Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi &quot;La Sapeinza&quot;</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliana Alimena</last_name>
      <phone>39-06-857-951</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia Universita - University di Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-79-228-280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita di Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-0577-586-429</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore dell' Universita</name>
      <address>
        <city>Trieste</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-040-399-2232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-73-699-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-20-599-9111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>31-71-526-9111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Amadori S, Suciu S, Selleslag D, et al.: Phase II-III study of gemtuzumab ozogamicin monotherapy versus best supportive care in older patients with newly diagnosed AML unfit for intensive chemotherapy: first results of the EORTC-GIMEMA AML-19 trial. [Abstract] Blood 112 (11): A-762, 2008.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

